FDA Approves Pfizer's COVID-19 Booster For Age 12 To 15

The FDA has authorized the use of a third dose of the Pfizer Inc PFE and BioNTech SE BNTX COVID-19 vaccine for children aged between 12 and 15 years.

  • The agency also narrowed the time for all booster shots to 5 months from 6 months after primary doses for people 12 years of age and older.
  • Related Link: Pfizer-BioNTech Reveals Updated Longer-Term Data On COVID-19 Shot In Adolescents.
  • The FDA also authorized the third shot for immunocompromised children aged 5 through 11 years.
  • The FDA said it reviewed published data and real-world evidence on the safety of booster doses provided by the Israeli Ministry of Health, including data from over 6,300 individuals 12-to-15 years of age who received a Pfizer shot.
  • Price Action: PFE shares are down 3.22% at $57.15, and BNTX stock is down 4.97% at $245 during the market session on the last check Monday.
  • Photo by x3 from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!